Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) has received a consensus recommendation of “Hold” from the five research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.50.
A number of brokerages recently commented on ANIX. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Wednesday, April 8th. Finally, Wall Street Zen lowered shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th.
Read Our Latest Report on Anixa Biosciences
Anixa Biosciences Stock Up 8.2%
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. Equities research analysts anticipate that Anixa Biosciences will post -0.31 earnings per share for the current year.
Insider Activity at Anixa Biosciences
In other news, CEO Amit Kumar purchased 21,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, June 12th. The shares were bought at an average cost of $2.50 per share, with a total value of $52,500.00. Following the completion of the purchase, the chief executive officer directly owned 630,812 shares in the company, valued at approximately $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 26.40% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. 683 Capital Management LLC bought a new stake in Anixa Biosciences during the fourth quarter worth about $355,000. ExodusPoint Capital Management LP bought a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $293,000. Susquehanna International Group LLP lifted its holdings in shares of Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after purchasing an additional 63,584 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $161,000. Finally, State Street Corp boosted its position in shares of Anixa Biosciences by 32.0% in the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after purchasing an additional 38,540 shares in the last quarter. 29.13% of the stock is currently owned by institutional investors.
About Anixa Biosciences
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Featured Articles
- Five stocks we like better than Anixa Biosciences
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
